Gilead Sciences (GILD): Cutting Numbers Slightly on Slower Switching - Leerink
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) but cut the price target to $112.00 from $114.00. The analyst underestimated the company’s US volume growth but also overestimated the rate of switching from legacy products onto new TAF-based regimens. As a result of the updates, the analyst now forecasts a slightly lower Revenue/TRx trend due to slower-than-expected switching to TAF based regimens from legacy combinations.
The analyst is expecting Gilead’s HIV products to generate WW sales of $20.5bn in 2021E vs. the previous forecast of $22.6bn.
Shares of Gilead Sciences closed at $81.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix (NFLX) PT Raised to $165 at Instinet Following Strong Results
- UBS Cuts Price Target on Morgan Stanley (MS) to $49; Reiterates Buy
- UBS Cuts Price Target on Qualcomm (QCOM) Following FTC Complaint
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!